| Literature DB >> 30805300 |
Ali Vaziri-Gohar1, Mahsa Zarei2,3, Jonathan R Brody4, Jordan M Winter1,5.
Abstract
[This corrects the article DOI: 10.3389/fonc.2018.00617.].Entities:
Keywords: metabolic dependencies; metabolism; pancreatic cancer; redox homeostasis; targeting metabolism
Year: 2019 PMID: 30805300 PMCID: PMC6371022 DOI: 10.3389/fonc.2018.00672
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Metabolic dependencies in PDA.
| Increased oxidative phosphorylation | Down regulation of Drp1 | ( |
| HuR | ( | |
| Increased biogenesis | HuR | Unpublished |
| Autophagy | Oncogenic KRAS | ( |
| NAD+ salvage pathway | miR-206 | ( |
| Macropinocytosis | Oncogenic KRAS | ( |
| Increased alanine uptake | Oncogenic KRAS | ( |
| Upregulation of ME1 | Oncogenic KRAS | ( |
| Upregulation of NRF2 | Oncogenic KRAS | ( |
| Upregulation of IDH1 | HuR | ( |
Clinical trials targeting key steps of PDA metabolism.
| ETC | Metformin + gemcitabine + ertotinib | II; Completed | NCT01210911 | ( |
| Metformin + paclitaxel | II; Completed | NCT01971034 | ( | |
| Metformin + gemcitabine/nab-paclitaxel | I; Recruiting | NCT02336087 | ||
| Metformin + mFOLFIRINOX | II; Active | NCT01666730 | ||
| Metformin + rapamycin | Ib; Active | NCT02048384 | ||
| Metformin + radiosurgery | I; Active | NCT02153450 | ||
| TCA cycle | CPI-613 | I; Completed | NCT01839981 | |
| CPI-613 + mFOLFIRINOX | I; Active | NCT01835041 | ( | |
| CPI-613 + gemcitabine/nab-paclitaxel | I; Active | NCT03435289 | ||
| Autophagy | HCQ | II; Completed | NCT01273805 | ( |
| HCQ + gemcitabine | I/II; Active | NCT01128296 | ||
| HCQ + gemcitabine + abraxane | I/II; Active | NCT01506973 | ||
| CQ + gemcitabine | I; Completed | NCT01777477 | ( | |
| Glutaminase | CB-839 | I; Active | NCT02071862 | |
HCQ, hydroxychloroquine; CQ, chloroquine; mFOLFIRINOX, modified FOLFIRINOX.